Impact of coffee on liver diseases: A systematic review

Liver International

Volumn 34, Issue 4, 2014, Pages 495-504

  Saab, Sammy ^a   Mallam, Divya ^b   Cox, Gerald A ^a   Tong, Myron J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Coffee; Liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAFFEINE; GAMMA GLUTAMYLTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALTERNATIVE MEDICINE; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER RISK; CHRONIC LIVER DISEASE; COFFEE; COFFEE INTAKE; DIETARY INTAKE; DISEASE SEVERITY; DRINKING BEHAVIOR; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; LABORATORY TEST; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; META ANALYSIS; MORTALITY; NONALCOHOLIC FATTY LIVER; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VIRUS HEPATITIS;

COFFEE; LIVER DISEASE;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; CAFFEINE; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 84895794335     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12304     Document Type: Review

References (81)

1. National Coffee Association USA. http://www.ncausa.org. Accessed February 2, 2013
2. Higdon JV, Frei B. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 2006; 46: 101-23.
3. Ponte S. The 'Latte Revolution'? Regulation, markets and consumption in the global coffee chain. World Dev 2002; 30: 1099-122.
4. Ruhl CE, Everhart JE. Association of coffee consumption with gallbladder disease. Am J Epidemiol 2000; 152: 1034-8.
5. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001; 50: 56-63.
6. Wu JN, Ho SC, Zhou C, et al. Coffee consumption and risk of coronary heart disease: a meta-analysis of 21 prospective cohort studies. Int J Cardiol 2009; 137: 216-25.
7. Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, et al. Coffee consumption and risk of stroke in women. Circulation 2009; 119: 1116-23.
8. Lopez-Garcia E, Van Dam RM, Li TY, et al. The relationship of coffee consumption with mortality. Ann Intern Med 2008; 148: 904-14.
9. Freedman ND, Park Y, Abnet CC, et al. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012; 366: 1891-904.
10. Kochanek KD, Xu J, Murphy SL, et al. Deaths: final data for 2009. Natl Vital Stat Rep 2011; 60: 1-166.
11. Younoussi Z, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol and Hepatol 2011; 9: 524-30.
12. Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. J Hepatol 2002; 36: 227-42.
13. Luk JM, Wang X, Liu P, et al. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007; 27: 879-90.
14. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34: 595-603.
15. Richmond JA, Bailey DE, Patel K, et al. The use of complementary and alternative medicine by patients with chronic hepatitis C. Complement Ther Clin Pract 2010; 16: 124-31.
16. Arnesen E, Huseby NE, Brenn T, et al. The TromsØ heart study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scand J Clin Lab Invest 1986; 46: 63-70.
17. Nilssen O, Førde OH, Brenn T. The Tromsø study: distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol 1990; 132: 318-26.
18. Nilssen O, Førde OH. Seven-year longitudinal population study of change in gamma-glutamyltransferase: the Tromsø Study. Am J Epidemiol 1994; 139: 787-92.
19. Tanaka K, Tokunaga S, Kono S, et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998; 27: 438-43.
20. Kono S, Shinchi K, Imanishi K, et al. Coffee and serum gamma-glutamyltransferase: a study of self-defense officials in Japan. Am J Epidemiol 1994; 139: 723-7.
21. Honjo S, Kono S, Ogawa S, et al. Coffee drinking and serum gamma-glutamyltransferase: an extended study of self-defense officials of Japan. Ann Epidemiol 1999; 9: 325-31.
22. Honjo S, Kono S, Ogawa S, et al. Coffee consumption and serum aminotransferases in middle-aged Japanese men. J Clin Epidemiol 2001; 54: 823-9.
23. Nakanishi N, Nakamura K, Nakajima K, et al. Coffee consumption and decreased serum gamma-glutamyltransferase: a study of middle-aged Japanese men. Eur J Epidemiol 2000; 16: 419-23.
24. Casiglia E, Spolaore P, Ginocchio G, Ambrosio GB. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993; 9: 293-7.
25. Pintus F, Mascia P. Distribution and population determinants of gamma-glutamyltransferase in a random sample of Sardinian inhabitants. Eur J Epidemiol 1996; 12: 71-6.
26. Poikolainen K, Vartiainen E. Determinants of gamma-glutamyltransferase: positive interaction with alcohol and body mass index, negative association with coffee. Am J Epidemiol 1997; 146: 1019-24.
27. Skurtveit S, Tverdal A. Sex differences in gamma-glutamyltransferase in people aged 40-42 years in two Norwegian counties. Drug Alcohol Depend 2003; 69: 103-6.
28. Urgert R, Meyboom S, Kuilman M, et al. Comparison of effect of cafetiere and filtered coffee on serum concentrations of liver aminotransferases and lipids: six month randomized controlled trial. BMJ 1996; 313: 1362-6.
29. Ikeda M, Maki T, Yin G, et al. Relation of coffee consumption and serum liver enzymes in Japanese men and women with reference to effect modification of alcohol use and body mass index. Scand J Clin Lab Invest 2010; 70: 171-9.
30. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005; 128: 24-32.
31. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. J Hepatol 2010; 51: 201-9.
32. Ruhl CE, Everhart JE. Coffee and teas consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129: 1928-36.
33. Corrao G, Zambon A, Bagnardi V, et al. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol 2001; 11: 458-65.
34. Gallus S, Tavani A, Negri E, La Vecchia C. Does coffee protect against liver cirrhosis? Ann Epidemiol 2002; 12: 202-5.
35. Corrao G, Lepore AR, Torchio P, et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. Eur J Epidemiol 1994; 10: 657-64.
36. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992; 136: 1248-57.
37. Klatsky AL, Armstrong MA, Friedman GD. Coffee, tea, and mortality. Ann Epidemiol 1993; 3: 375-81.
38. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006; 166: 1190-5.
39. Tverdal A, Skurtveit S. Coffee intake and mortality from liver cirrhosis. Ann Epidemiol 2003; 13: 419-23.
40. Ong A, Wong VW, Wong GL, Chan HL. The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. Liver Int 2011; 31: 1047-53.
41. Wong G, Wong V, Choi P, et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 2008; 6: 1027-35.
42. Freedman ND, Everhart JE, Hoefs JC, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. J Hepatol 2009; 50: 1360-9.
43. Freedman ND, Curto TM, Lindsay KL, et al. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011; 140: 1961-9.
44. Costentin CE, Roudot-Thoraval F, Zafrani ES, et al. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 2011; 54: 1123-9.
45. Carrieri MP, Cohen J, Salmon-Ceron D, Winnock M. Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH. J Hepatol 2012; 56: 745-7.
46. Birerdinc A, Stepanova M, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 35: 76-82.
47. Catalano D, Martines GF, Tonzuso A, et al. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2010; 55: 3200-6.
48. Gutièrrez-Grobe Y, Chàvez-Tapia N, Sànchez-Valle V, et al. High coffee intake is assocaited with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol 2012; 11: 350-5.
49. Molloy JW, Calcagno CJ, Williams CD, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. J Hepatol 2012; 55: 429-36.
50. Anty R, Marjoux S, Marinè-Barjoan E, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012; 57: 1090-6.
51. La Vecchia C, Ferraroni M, Negri E, et al. Coffee consumption and digestive tract cancers. Cancer Res 1989; 49: 1049-51.
52. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85: 498-502.
53. Gallus S, Bertuzzi M, Tavani A, et al. Does coffee protect against hepatocellular carcinoma. Br J Cancer 2002; 87: 956-9.
54. Gelatti U, Covolo L, Franceschini M, et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005; 42: 528-34.
55. Tanaka K, Hara M, Kawazoe S, et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci 2007; 98: 214-8.
56. Montella M, Polesel J, Franceschi S, et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007; 120: 1555-9.
57. Ohishi W, Fujwara S, Cologne JB, et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17: 849-54.
58. Shimazu T, Tsubono Y, Kuryama S, et al. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005; 116: 150-4.
59. Inoue M, Kurahashi N, Iwasaki M, et al. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomark Prev 2009; 18: 1746-53.
60. Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97: 293-300.
61. Hu G, Tuomilehto J, Pukkala E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. J Hepatol 2008; 48: 129-36.
62. Johnson S, Koh WP, Wang R, et al. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese health study. Cancer Causes Control 2011; 22: 503-10.
63. Leung WW, Ho SC, Chan HLY, et al. Moderate Coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. J Epidemiol Community Health 2011; 65: 556-8.
64. Kurozawa Y, Ogimoto I, Fukudo K, et al. Dietary habits and risk of death due to hepatocellular carcinoma in a large scale cohort study in Japan. Kurume Med J 2004; 51: 141-9.
65. Kurozawa Y, Ogimoto I, Tamakoshi A, et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005; 93: 607-10.
66. Wakai K, Kurozawa Y, Tamakoshi A, et al. Liver cancer risk, coffee, and hepatitis C virus infection: a nested case-control study in Japan. Br J Cancer 2007; 97: 426-8.
67. Ohfuji S. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case-control study. Hepatol Res 2006; 36: 201-8.
68. Torres DM, Harrison SA. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology. 2013; 144: 670-2.
69. Urgert R, Essed N, Van der Weg G, Kosmeijer-Schuil TG, Katan MB. Separate effects of the coffee diterpenescafestol and kahweol on serum lipids and liver aminotransferases. Am J Clin Nutr 1997; 65: 519-24.
70. Gressner OA, Lahme B, Rehbein K, et al. Pharmacological application of caffeine inhibits TGF-Beta-stimulated connective tissue growth factor expression in hepatocytes via PPAR-gamma and SMAD2/3-dependent pathways. J Hepatol 2008; 49: 758-67.
71. Kalthoff S, Ehmer U, Freiberg N, et al. Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010; 139: 1699-710.
72. Shim SG, Jun DW, Kim EK, et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol 2013. Epub ahead of print.
73. Okano J, Nagahara T, Matsumoto K, Murawaki Y. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin Pharmacol Toxicol 2008; 102: 543-51.
74. McMahon M, Itoh K, Yamamoto M, et al. The cap 'n' collar basic leucine zipper transcription factor Nrf2 controls not only the basal expression of intestinal detoxification and glutathione biosynthetic enzymes but also their induction by cancer chemopreventive agents. Cancer Res 2001; 61: 3299-307.
75. Cavin C, Mace K, Offort EA, Schilter B. Protective effects of coffee diterpenes against aflatoxin B1-inuced genotoxicity: mechanisms in rat and human cells. Food Chem Toxicol 2001; 39: 549-56.
76. Lam LKT, Spamins VL, Wattenberg LW. Isolation and identification of kahweol and cafestol palmitate as active constituents of green coffee beans that enhance glutathione S-transferase activity in the mouse. Cancer Res 1982; 42: 1193-8.
77. Huber WW, Scharf G, Rossmanith W, et al. The coffee components kahweol and cafestol induce gamma-glutamylcysteine synthetase, the rate limiting enzyme of chemoprotective glutathione synthesis, in several organs of the rat. Arch Toxicol 2002; 75: 685-94.
78. Huber WW, Parzefall W. Modification of N-acetyltransferases and glutathione S-Transferases by coffee components for cancer risk. Methods Enzymol 2005; 401: 307-41.
79. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-9.
80. Cadden SH, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. Aliment Pharmacol Ther 2007; 26: 1-7.
81. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J 2003; 20: 54-60.